Full Text View
Tabular View
No Study Results Posted
Related Studies
Drainage of Malignant Extrinsic Ureteral Obstruction Using the Memokath Ureteral Stent
This study is currently recruiting participants.
Study NCT00166361   Information provided by Mayo Clinic
First Received: September 12, 2005   Last Updated: January 26, 2006   History of Changes

September 12, 2005
January 26, 2006
March 2004
 
  • Treatment efficacy in relief of extrinsic ureteral obstruction in comparison to historic efficacy of standard double-J plastic ureteral stents as cited in the urologic literature
  • Perioperative and postoperative complications and side effect profiles, including failure of stent insertion, complications of stent insertion, and postoperative complications
Same as current
Complete list of historical versions of study NCT00166361 on ClinicalTrials.gov Archive Site
 
 
 
Drainage of Malignant Extrinsic Ureteral Obstruction Using the Memokath Ureteral Stent
Long-Term Temporary Drainage of Malignant Extrinsic Ureteral Obstruction Secondary to Inoperable Pelvic or Abdominal Malignancies Using the Memokath 051 Ureteral Stent

The purpose of this study is to evaluate the safety and efficacy of the Memokath 051 ureteral stent as a long-term temporary and minimally invasive means of providing ureteral drainage in the setting of malignant extrinsic ureteral obstruction secondary to inoperable abdominal or pelvic malignancies. Up to 15 adults who have extrinsic ureteral obstruction secondary to an inoperable abdominal or pelvic malignancy and need ureteral stent drainage will undergo outpatient placement of the ureteral stent. Ongoing monitoring will continue for as long as the stent is in place.

 
 
Interventional
Treatment, Non-Randomized, Open Label, Active Control, Parallel Assignment
Ureteral Obstruction
Device: Memokath 051 Ureteral Stent
 
 

*   Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
 
Recruiting
25
 
 

Inclusion Criteria:

  • Presence of extrinsic ureteral obstruction secondary to inoperable pelvic or abdominal malignancy.
  • Life expectancy greater than 4 months.
  • Adult patient (18 years of age or older)
  • Preoperative medical examination clearing the patient for general anesthesia
  • No active urinary tract infection by urinalysis and urine culture
Both
18 Years and older
No
 
United States
 
NCT00166361
 
255-03
Mayo Clinic
Engineers & Doctors Wallsten Medical Group
Principal Investigator: Lance A Mynderse, M.D. Mayo Clinic
Mayo Clinic
September 2005

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP